A Study Evaluating TRIV-509 in Atopic Dermatitis

To be part of this study, you need to be an adult between 18 and 75 years old. You must have eczema (atopic dermatitis) that is considered moderate to severe, meaning it's causing significant symptoms and is active at the time of the study.

There are certain reasons why you might not be able to join. For example, if you have other serious or uncontrolled health problems. Also, if you've recently used certain treatments for your eczema, such as strong creams, light therapy, or specific medicines that affect your immune system, you might need to wait a certain period before you can participate. This 'waiting period' is to make sure that any effects seen in the study are from TRIV-509 and not from previous treatments.

If you decide to take part in this study, the total time commitment will be up to 57 weeks. This includes an initial check-up period that could last up to 30 days to make sure you meet all the requirements. During the main part of the study, you will receive either TRIV-509 or a dummy treatment (placebo) for 16 weeks, taking 4 doses of that treatment. Then, you will switch to the other treatment (the one you didn't get first) for another 16 weeks, also taking 4 doses. You will have regular visits to the clinic for assessments, which will likely include physical examinations, blood tests, and discussions about how you're feeling and how your eczema is changing. All study-related medication and assessments will be provided.